Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ludovica Mollica
Observed name:
L. Mollica
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele
Observed institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele
ORCID:
0009-0002-0972-2803
Observed ORCID:
0009-0002-0972-2803
OpenAlex ID:
A5129654318
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
2025
·
Sara Oresti
, Fabio Salomone
, et al.
·
EClinicalMedicine
·
5
PDF
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study
2026
·
Ludovica Mollica
, Elena Tassi
, et al.
·
Clinical Lung Cancer
Molecular bycatch in early-stage NSCLC: Keep, discard, or redefine?
2026
·
Nikolaj Frost
, Ludovica Mollica
, et al.
·
European Journal of Cancer
562eP Tumor, host and treatment related predictive factors for immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI)
2026
·
F.M. Venanzi
, D. Zotti
, et al.
·
ESMO Open
A viable human lung cancer tissue collection (LCTC) to accelerate translational research
2026
·
Virginia Guzzeloni
, Alessandra Bartolucci
, et al.
·
Cancer Treatment and Research Communications
Show more works
View as search
Works count:
5
Citation count:
5
H-index:
1
I10-index:
Year
Topic
Type